The Obamacare Stock Portfolio Emergency Room

[SaltyMutt]

PGLA

Company Background

Progen Pharmaceuticals Limited is an Australia-based biotechnology company. The principal activities of the Company during the fiscal year ended June 30, 2012 (fiscal 2012), included discovery, research and development of potential biopharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and assurance of biological products. The Company operates in two segments: research and development and manufacturing. The primary activities of the research and development division were Preclinical and clinical development of PG545, and the clinical development of other drug candidates including PG11047 and the Phase 2 PI-88 melanoma program. It operates a currently Good Manufacturing Practices (cGMP), certified manufacturing facility that provides contract manufacturing services to the biotechnology industry. The Company's pipeline includes angiogenesis, cell proliferation and epigenetics series.

http://www.progen.com.au